Schedule an Appointment
ThermaGenix Inc

ThermaGenix Inc

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

ThermaGenix Inc

Location: Natick, MA

Sector: Life Sciences.

Add to Shortlist
Express Interest

ThermaGenix is committed to empowering scientists all over the world with the highest performing Polymerase Chain Reaction (PCR) additives. Our innovative and universal PCR additives ThermaStop™, ThermaGo™ and ThermaStop-RT™ augment polymerase specificity and fidelity, enhancing quantitative end-point data accuracy and analysis and achieving more homogeneous amplicons for downstream applications.

 

These technologies significantly enhance analysis of RNA substrates as well as DNA substrates. From genotyping to Gibson assembly, next generation sequencing sample preparation to diagnostics, ThermaGenix technology will maximize PCR and RT-PCR performance.

Business Documents

MG cp Summary

ThermaStop™, ThermaGo™ and ThermaStop-RT™ prevent DNA Polymerases and Reverse Transcriptases from acting outside of  precise temperature ranges, thereby minimizing spurious side reactions and off-target activity. TGX is the first company to offer patented molecular reagents that control the key enzymes in very specific temperature ranges- which results in High-Precision PCR.

 

Key Features of ThermaStop:

• Replaces Hot-Start, cheaper & more effective – benefit for all forms of PCR

• Stabilizes Taq Polymerase for Extended Periods of Time- benefit for PCR

• Prevents mis-priming during reverse transcription of RNA

• Enhances Multiplexing – benefit for PCR

• Acts as a Cold Stop – benefit for NGS

• First Hot-Start for RT-PCR – benefit for NGS

 

Key Features of ThermaGo:

• First reagent to suppress product-product interactions during amplification

• Works with both antibody hot start and chemical hot start

• Enhances End-Point Genotyping using Symmetric PCR

• Suppresses chimera formation – benefit for NGS and Gibson assembly

 

Key Features of ThermaStop-RT:

• Provides Superior Hot-Start for RT-PCR

• Significantly improves Sensitivity and Specificity in RT-PCR

• Provides for Significant Increase in RNA Yields as reported and far better One-Step or Two-Step RT-PCR results

Entry into Global PCR Marketplace:

VERY Large and Growing Global Markets. ThermaGenix products are unique and value-adding for all aspects of PCR marketplace.

 

Entry in Global Next-Gen Sequencing (NGS) Markets:

VERY Large and Growing Global Markets. ThermaGenix products are unique and value-adding for all aspects of NGS marketplace. It is estimated that use addition of ThermaGenix reagents in NGS Product and Library preparation that approx.. 25% of NGS costs can by eliminated- saving over $100M annually.

 

Entry into VERY Large and Expanding Liquid Biopsy Marketplace:

ThermaGenix represents an “Intel-Inside” like opportunity to have an investment into the largest growth opportunity to come to Life Science/Cancer Diagnostics in the last decade, and for years to come.

Peter J Coassin – President and CEO

Mr Coassin is an experienced and successful inventor, entrepreneur and leader.  Since graduation Mr. Coassin has invented technologies and worked with leading academic scientists (Hubert Koester, Edwin Southern, John Fenn, Roger Tsien, Ron Davis and most recently Lawrence Wangh) to bring to market many different technologies including DNA Synthesizers, Peptide Synthesizers, DNA Arrays, Capillary Electrophoresis based DNA sequencing, cellular technologies and miniaturization, advanced microscopy and now, truly revolutionary additives to improve critical biotechnology enzyme processes.

 

Mr Coassin has worked within large Fortune 500 companies to produce products (Millipore, Beckman-Coulter, Vertex Pharmaceuticals) as well as a range of startups including CoWest Instruments – Sold to Millipore 1985, Aurora Biosciences –   Sold to Vertex in 2001, Aurora Discovery – sold to Beckman in 2006, Aurora Biotechnologies – merged to Nexus 2009 and sold to Brooks Automation 2011.

 

 

Lawrence J Wangh, Founder and CSO

Professor Lawrence, received his undergraduate degree in biology at Brandeis University in 1968 and his Ph.D. in biochemistry from The Rockefeller University in 1973.  He then went to England as a Helen Hay Whitney Fellow and work at the Medical Research Council laboratories in Cambridge and London.  In 1977 he returned to the Biology Department of Brandeis University to teach courses in developmental biology, reproductive biology, and evolution.  In parallel he established a laboratory aimed at doing basic research in those same fields.  In the course of that work he and his laboratory colleagues invented a novel method for non-symmetric amplification of very small amounts of DNA.

 

From 1997 through 2016, with approximately 10 million dollars of support from grants and biotechnology companies, he and his team invented a suite of synergistic technologies that enhanced their new PCR method and its use in many fields, including quantitative measurements of DNA and RNA in single cell, highly informative single-tube diagnosis of cancer gene targets, and detection of numerous infectious diseases – including extensively drug resistant tuberculosis.

 

After nearly forty years on the Brandeis faculty, Professor Wangh and his team: Aquiles Sanchez, Ph.D., John Rice M.S., and Kenneth Pierce, Ph.D. launched ThermaGenix, Inc. in 2017 in order to commercialize their revolutionary PCR reagents and methods. ThermaGenix is committed to enhancing the quality of life by selling its technologies for high precision analysis of very small quantities of nucleic acids to researchers, biotechnologists, and medical professionals worldwide.

 

 

Charles Powell, Chief Commercial Officer

Mr. Powell has spent the majority of his professional career in a variety of Life Science Sales and Marketing roles and assignments starting out as a field-sales representative with Beckman Instruments. Mr. Powell joined Aurora Discovery in May 2004 as Vice President, Sales and Marketing- eventually becoming Chief Commercial Officer and Director.

 

Aurora evolved over 7 years – merging with Nexus Biosystems in 2009 before being bought by Brooks Automation in 2011. In October 2015 Mr. Powell bought the Aurora Business back from Brooks Automation. In January 2017 Mr. Powell joined Thermagenix as Chief Commercial Officer.


Sequella Inc.

Sequella Inc.

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

Sequella Inc.

Location: Rockville, MD

Sector: Life Sciences .

Add to Shortlist
Express Interest

Sequella is a private, clinical stage pharmaceutical company that addresses the challenge of antibiotic resistant bacterial diseases by discovery and development of first in class antibiotics with novel mechanisms of action.

Business Documents

MG cp Summary

The clinical stage drugs produced by Sequella Inc. are SQ109 and sutezolid: both are being independently advanced for the treatment of drug resistant tuberculosis (MDR-TB).

SQ109 completed a successful MDR-TB registration trial in Russia: application for commercial approval will be filed and Sequella will receive product royalties. Both SQ109 and sutezolid are ready to enter pivotal trials in the US/EU that, if successful, will lead to NDA filing for accelerated registration in both territories. Registration in the U.S. of SQ109 for MDR-TB will provide Sequella with a priority review voucher (PRV) that can be monetized as part of a financing or at receipt: average sales price of PRV since inception is $178M. SQ109 has also been evaluated in an early stage clinical trial for treatment of gastritis (Helicobacter pylori in-fections).

SQ641 is in late pre-clinical development for the treatment of Clostridium difficile induced diarrhea, a deadly healthcare and community acquired infectious disease. Sequella also has a large chemical library of small molecule compounds created around active pharmacophores that can be screened on other important antibiotic resistant bacteria.

Late-stage products (reduced risk) – One drug, SQ109, has successfully completed a registration trial in Russia, meeting both safety and efficacy endpoints; sutezolid has completed a successful Phase 2a study in TB patients, with excellent early bactericidal activity

 

Drugs that address drug-resistant bacterial infections with novel mechanisms of action – Few companies are developing drugs for antibiotic resistant infections, despite clear need: in particular, few companies have or are developing new drugs for TB and no companies are developing drugs for H. pylori, which our drugs address

 

TB will always be treated with ≥ 3 drugs because of resistance development – Companies that are developing new TB drugs are looking for other compatible drugs with which to pair their drugs and make a new safer and more effective drug regimen, so all companies are collaborators, not competitors

 

Drugs in development are either new or improved versions of existing drugs – SQ109 is a new drug that acts in multiple ways to kill TB, no other drugs in clinical development kill TB in the same way. Sutezolid is an improved version of Zyvox (linezolid) and is expected to have similar efficacy and a better safety profile that allows for long term dosing. SQ641 is from a whole new class of antibiotics never before commercialized.

Carol A. Nacy, Chief Executive Officer Dr. Nacy is an accomplished scientist and businesswoman, with 20 years of basic science research and science management in academic settings (Fellow of the American Academy of Microbiology) and an additional 25 years of starting companies and leading science for product development in three U.S.-based biotechnology companies. She and the management team took her first company public on NASDAQ and her second company was acquired by a large biotechnology company. Her passion is in understanding and devising ways to prevent or treat infectious diseases that are global health threats, especially antibiotic resistant bacteria. She co-founded Sequella in 1997 and has led her team to discover and develop several novel antibiotics now in clinical trials that address diseases that infect billions of people worldwide, kill millions of people annually, and are underserved by pharmaceutical and biotechnology companies.

 

Mark Rampy, Chief Business Officer  Dr. Rampy has over twenty years of experience in the biotechnology and pharmaceutical sectors, including leadership roles at early stage and venture-backed companies, and mid-large cap public pharmaceutical/biotechnology companies.  His areas of expertise include business/corporate strategy, business development, structure, negotiation and closing of complex licensing transactions and strategic alliances, as well as technology and product development.  Prior to Sequella, he was CEO of several start-ups (Theraly Pharmaceuticals, and CohBar, Inc), VP Business Development Biologics and Specialty Products, Teva Pharmaceuticals, Founder and Chief Business Officer of CoGenesys, Inc. a company which was acquired by Teva. Prior to CoGenesys, he was with Human Genome Sciences, Inc. for eleven years, in positions of increasing responsibility in R&D and Business Development, the most senior of which was Head of Business Development.​

 

David Mc Neeley, MD, Chief Medical Officer Dr, Mc Neeley is an MD and specialist in pediatric infectious diseases, public health and tropical medicine. He was on the faculty of Weill Cornell Medical Center in the Division of Pediatric Infectious Diseases, working primarily in HIV and TB clinics, as well as general pediatric infectious disease clinic and in-hospital consultations, including rotations through Memorial Sloan-Kettering Medical Center. He has worked extensively in international health settings, including serving as medical director of an all-service hospital and an extensive community health program serving nearly 250,000 people. He conducted clinical and field research in bacterial infections, tuberculosis, human immunodeficiency virus infection and parasitic diseases such as schistosomiasis and filariasis. For the past 14 years, Dr. Mc Neeley has worked in anti-infective drug development (antibiotics, antivirals, and anti-parasitic drugs). For the past 14 years, Dr. Mc Neeley has worked in anti-infective drug development (antibiotics, antivirals, and anti-parasitic drugs) in large pharmaceutical companies (Johnson & Johnson, Novartis) and brought the first new TB drug, bedaquiline, through the clinic and to worldwide registration for J&J.

 

Leo Einck, VP Industry Affairs Dr. Einck has been building companies for the last 33 years: he was the 1st employee of Hemispherix and built out manufacturing facilities and executed clinical trials; he was the 8th employee of EntreMed and managed the relationship with a Harvard research group whose technology enabled the company to have an initial public offering; and he founded Sequella and Sequella Global TB Foundation with Dr. Nacy and has participated in all aspects of growing the company. His current role includes managing the GMP manufacturing and testing of Sequella’s antibiotics and research on TB diagnostics.


Protected: Tosk, Inc.

Protected: Tosk, Inc.

This content is password protected. To view it please enter your password below:

Wellesley Pharmaceuticals

Wellesley Pharmaceuticals

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.

Book a Conference Call
Get More Information

Wellesley Pharmaceuticals

Location: Newtown, PA

Sector: Life Sciences

.

Add to Shortlist
Express Interest

Wellesley Pharmaceuticals, LLC was founded to ensure that the ability of Nocturol™ to reduce and sometimes eliminate nocturia symptoms can be disseminated to help the hundreds of millions of people who can benefit from it.   Nocturol is a drug to treat nocturia, the frequent need to urinate at night.  This sometimes-deadly condition afflicts 2.4 billion people and causes insomnia, fatigue, depression, lower quality of life, higher rates of heart disease, stroke, long term brain damage, and deadly falls.

Business Documents

MG cp Summary

Huge unmet medical need – 2.4 billion people suffer from nocturia, which causes insomnia, fatigue, depression, lower quality of life, higher rates of heart disease, stroke, long term brain damage and deadly falls.

 

No viable competition – There is one FDA approved drug to treat nocturia and it demonstrated a 0.2 void/night benefit compared to the placebo.  Our result was 4.5 times better than that. Their drug has a black box warning about the dangers of hyponatremia.  We had zero side effects reported even among patients using 2 or 3 times the recommended dose.

 

Strong patent portfolio – Our patent lawyer had been named one of the top 1000 patent lawyers in the world six years in a row.  Dr. Ping Wang has never had a patent even challenged, much less overturned.  Our patents include doses ranging from 5mg (which is useless) to 2000mg (which could be deadly).  We believe we have a huge wall of IP around our invention.

Instant efficacy – Our drug is to be taken 30 minutes before bedtime since it is effective in 30 minutes.

 

Lack of side effects – We are using about 20% of the recommended daily dose of the two component drugs for a 10-year-old child.  If it is safe for a 10-year-old to take 5 times per day, we think it should be very safe for most adults to take once per night.

 

Superior efficacy – Compared to placebo, our clinical trial demonstrated 4.5 times higher efficacy than the only FDA approved drug for nocturia.

 

High profit margins – As an LLC, we pay no corporate income tax.  As a virtual corporation, we have almost no overhead expenses.  We have only one full time employee.  We expect net income margins to approach 95% of revenue.

David A. Dill, CEO and President

David Dill is the inventor of Nocturol and the founder of Wellesley Pharmaceuticals, LLC.  Nine years ago he made six changes in his life and since then has over 100 inventions.  When he realized that one of them could have a major impact on the world, he left his CFO position to focus fulltime on nocturia, which killed his father-in-law and leads to thousands of deaths per day.   He graduated summa cum laude from Princeton University in 1973 with a degree in economics.  He graduated from MIT’s Sloan School of Management in 1975 with a Master’s degree in finance and marketing.   He spent 19 years at IBM rising to CFO of a $2 billion business unit.  Since then he was VP Finance at General Instrument and CFO at 7 venture backed companies in 7 different industries, including Worldgate Communications, PlasticsNet, StorageApps, Digital 5, Telewares, Orchestria, and Undertone.   Key Career Milestones Achieved: One IPO (Worldgate Communications in 1999), one sale of a company for $350 million (StorageApps sold to HP in 2001), over 100 inventions in the last 9 years.


Nativis Inc.

Nativis Inc.

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

Nativis Inc.

Location: Seattle, Washington

Sector: Life Sciences

.

Add to Shortlist
Express Interest

Nativis has invented a groundbreaking therapeutic device technology that uses ultra-low radio frequency energy (ulRFE®) to interrupt disease mechanisms on the molecular and genetic levels – without chemicals or radiation. Nativis ulRFE is able to replicate the biological activity of a broad range of molecules including proven drugs, siRNA, mRNA, and endogenous compounds like hormones.  The resulting therapeutic product profile provides localized delivery of a proven mechanism of action, avoiding systemic toxicity, and allowing for cost-effective combination therapy (multiple targets on one device).  The therapeutic benefit is delivered via a simple-to-use investigational device called Nativis Voyager®, pictured below.  The controller weighs 6 ounces and the coil can be shaped to deliver the ulRFE® field to the desired areas of the body, avoiding exposure of other organs to maximize safety.

Business Documents

MG cp Summary

First breakthrough therapy in brain cancer – Most drugs don’t penetrate the blood brain barrier, consequently brain cancer drugs have not improved GBM outcomes in over 20 years. Nativis uniquely treats brain cancer in a way that minimizes safety and has potential to improve survival to unprecedented extent.

 

Fast to market HDE pathway – From identifying an HDE opportunity to regulatory submission takes roughly six months for Nativis, leveraging our ability to mimic existing mechanisms and rapidly enter preclinical and clinical testing.  From FDA submission to approval is roughly 6 months so the entire process takes about a year, dramatically less than a drug pathway.

 

Unique approach to cancer immunotherapy – The immuno-oncology (I/O) market is exploding, from $6 billion sales in 2017 to more than $20 billion forecasted within 5 years.  I/O drugs are not able to pass the blood-brain barrier and have significant toxicity issues.  Voyager provides localized therapy minimising toxicity, while leveraging the industry’s identification of key I/O targets (e.g. PD1, PDL1, CTLA4) for rapid progress into clinical trials.  Voyager has already been used to treat 9 patients using anti-PD1 and anti-CTLA4 mechanisms, moving much faster and less expensively than a comparable drug program.

 

Ability to leapfrog current cancer therapeutics – Cancer experts are agreed that combination therapy is critical.  Voyager uniquely can deliver combination therapy (multiple mechanisms played sequentially on a single device) in a way that is cost-effective and minimizes systemic side effects.

 

Beyond cancer, rapid entry to pain, inflammation, and other therapeutic areas – Nativis has identified opportunities in pain, inflammation, and infectious diseases where there are large markets with unmet needs that match up with the Voyager platform advantages.  For example the global anti-TNF drug market (treating arthritis and other inflammatory diseases) is over $40 billion and would be bigger if it were not held back by patient concerns about chronic immuno-suppression side effects.  Voyager has potential to deliver anti-TNF mechanism without immunosuppression, as well as providing localized pain relief.

 

Multiple vertical opportunities beyond human health – Nativis Voyager has been tested in over 300 dogs with naturally occurring cancers, showing promising signs of efficacy in over 20 tumor types.  Discussions are underway with veterinary health companies who are interested in licensing Voyager for companion animal cancer.  A joint research program is underway with an AgBio company that is testing how Nativis technology can revolutionize plant and livestock agribusiness.  Nativis has demonstrated the ability to increase lipid production in algae culture, resulting in interest from industrial biotech companies.  In all these areas beyond human health, Nativis will not invest its own money in R&D – instead the partners who identify opportunities will pay for the R&D and commercialization, with business impact accretive to Nativis.

Our initial focus is on the treatment of patients with brain cancer who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects.  Initial results from the human clinical trial (n=64) of Nativis Voyager® device in recurrent glioblastoma multiforme (rGBM) brain tumors has shown no device-related adverse events and promising signs of efficacy.  The company completed its first licensing agreement for this indication in April 2017 with Teijin Pharma, a large Japanese pharma company, and discussions continue regarding additional ulRFE® licenses to treat other conditions in Japan.  Other licensing discussions are underway with multiple global pharmaceutical companies.   In addition to GBM, Nativis is pursuing three rare pediatric brain cancers in the US (medulloblastoma, diffuse midline glioma, and ependymoma) through an accelerated FDA pathway called Humanitarian Device Exemption (HDE).  We expect to have FDA approval for these three indications by end of year 2018 and to have our first commercial revenue in early 2019, with the potential to reach $100 million in revenue in these three indications alone by 2022.  Nativis is targeting one to two HDE approvals per year for the foreseeable future, with HDE revenues totaling $200 million by 2023.

Chris E. Rivera – President, Chief Executive Officer and Chairman of the Board

Chris brings more than 30 years of experience in the biotechnology industry. Chris was the Founder and CEO of Hyperion Therapeutics, which was acquired by Horizon Pharma in 2015, the Senior Vice President and head of Commercial Operations at both Tercica, where he led the cross-licensing transaction between Tercica and Ipsen, and Genzyme Therapeutics, where he built and ran Genzyme’s US renal Commercial Operations, he also helped launch Genzyme’s renal division globally. Prior to Genzyme, he helped build Cephalon and Centocor’s initial commercial infrastructures.

 

Kenneth Ferguson, PhD – Chief Scientific Officer

Ken is Chief Scientific Officer at Nativis. Prior to joining Nativis, Ken was vice president and chief development officer at Omeros Corporation, CEO of VacTX, and spent 16 years at ICOS Corporation in research and development, where he was Product Development Team Leader and later the Chief Scientific Officer and Board member of the Lilly ICOS Joint Venture. Ken is a graduate of Cornell University and The University of Texas Health Science Center at Dallas. His doctoral research with Dr. Al Gilman focused on signal transduction, specifically the mechanism by which G proteins participate in the action of G protein-coupled receptors. Ken completed post-doctoral studies with Dr. Michael Wigler at Cold Spring Harbor Laboratory with a focus on oncogenes and the cell cycle.

 

Xavier A. Figueroa, PhD – Director, Pre-clinical Development

Xavier is the principal scientist for Nativis overseeing pre-clinical research and the application of Nativis technology in multiple disease areas. He has more than 20 years of experience in basic and neurological clinical research, including Alzheimer’s research, neuron biology, cancer research, bioengineering and biophysics. He has advised emerging biotechnology companies, most notably Cytokinetics and ENG3. Xavier has also served on non-profit Scientific Advisory boards for such organizations as the Brain Health and Healing Foundation and published broadly in multiple areas of science and medicine. Xavier received his doctoral degree in Neurobiology & Behavior from the University of Washington. His doctoral training was followed by two post-doctoral fellowships within the University of Washington’s Department of Bioengineering. He is currently an affiliate assistant professor in the School of Medicine at the University of Washington.

 

David Matteson, MPH, MEd, MPA – Investor Relations and Education

David is a seasoned business leader and strategist, who has dedicated his career to advancing health innovations, services, and products into the market place. Prior to joining Nativis full time in 2012, he consulted to early- and growth-stage companies in healthcare to develop strategic plans, raise capital, craft public policy campaigns, design and implement marketing and branding programs, manage company growth and change, and foster high-performance teams at both the board and C-suite levels. As an executive coach he has worked with dozens of entrepreneurs to hone their ideas into viable business structures and lead their ventures through the volatile journey to market. David has a diverse background that spans five academic preparations and numerous executive positions across several industries. This broad base of training and experience provides a unique, integrated, and long-view perspective that is valuable when designing integrated business structures and strategies to move innovation into the market. He has a proven track record of brokering and managing multi-disciplinary teams to tackle complex business opportunities.

 

Michael Mischke-Reeds, MA – SVP of Business Development

Michael has over 25 years of leadership experience in life sciences companies, having worked as a startup biotech executive and a management consultant, specializing in biotechnology. After studying biology and management science at Stanford University, he co-founded startup companies Fast Track Systems (software to support pharmaceutical clinical development) and Chiron Informatics (disease management software for HIV). His management consulting career started at Strategic Decisions Group (world leader in pharmaceutical asset valuation and portfolio management) and then cofounded Keelin Reeds Partners (biotech-focused consulting firm offering valuation, strategy, and transaction support). Michael is currently Senior Vice President of Business Development for Nativis, where he leads partnering activities as well as strategy and valuation.

 

Donna Morgan Murray, PhD – Chief Regulatory Officer

Donna is the Chief Regulatory Officer for Nativis. A seasoned healthcare professional, she has more than 30 years of experience in the biotechnology and pharmaceutical industries. She’s authored more than 60 publications and served on several non-profit boards and organizations. Donna holds a PhD from the University of Texas Health Science Center at Houston.

 

Eric Peterson – Director of Development and Manufacturing

Eric brings more than 20 years of experience in developing, manufacturing and commercializing innovative medical devices in fast growing start-up companies. He serves as the Director of Development and Manufacturing at Nativis, where he is responsible for leading design, development and manufacturing operations with strategic partners while ensuring compliance with FDA and ISO standards.

 

Steven Pope, MA (Oxon) JD – Corporate Secretary and Sr. VP, General Counsel

Steven is responsible for overseeing the legal affairs of the Company, including contracts, securities, governance, intellectual property, and employment matters. Prior to joining Nativis in 2010, Steven was a Partner at Perkins Coie LLP. Steven received his J.D. cum laude from Seattle University School of Law where he was a member of the Law Review, his M.A. from the University of Oxford, and his B.A. summa cum laude from Gonzaga University.

 

Gabriel Vogeli, PhD – Senior Distinguished Scientist

Gabriel, Distinguished Scientist, is the former Director of Molecular Biology for Dendreon Corporation, former Senior Scientist at Upjohn Company/Pharmacia-Upjohn and Senior Staff Fellow at the National Institutes of Health. Gabriel holds a PhD from the University of Zurich, and was a Postdoctoral Fellow at Yale University.